The Effect of Dietary Fat Content on the Recurrence of Pancreatitis (EFFORT)
The Effect of Dietary Fat Content on the Recurrence of Pancreatitis (EFFORT): Protocol of a Multicentre Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Péter Hegyi, MD, PhD, DSc
- Phone Number: +36703751031
- Email: hegyi2009@gmail.com
Study Contact Backup
- Name: Félix Márk Juhász, MD
- Phone Number: +36203733370
- Email: flixjuhsz@gmail.com
Study Locations
-
-
-
Budapest, Hungary
- Recruiting
- Division of Pancreatic Diseases, Heart and Vascular Center, Semmelweis University
-
Contact:
- Péter Hegyi, Prof.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Individuals with at least two episodes of acute pancreatitis in the 2 years preceding the inclusion with
- The last episode being idiopathic, who are
- Older than 14 years.
Exclusion Criteria:
- Individuals already receiving regular nutritional guidance (with medical indication),
- Individuals in critical condition or in terminal stage of cancer (with an expected survival <2 years) ,
- Individuals undergoing treatment for active malignancy,
- Individuals with uncontrolled diabetes mellitus (admitted lack of compliance with antidiabetic therapy / HbA1c >6.5% / indication of uncontrolled diabetes mellitus in last 24 months' anamnesis / newly discovered diabetes mellitus)
- Individuals with known cholecystolithiasis
- Individuals who are pregnant or nursing
- Individuals with a BMI < 18.5
- Individuals who are regularly receiving systemic corticosteroids
- Individuals consuming more alcohol than: 5 units per day or 15 units per week for men; 4 units per day or 8 units per week for women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Reduced fat arm
Daily calorie intake will be composed of 15% fat, 65% carbohydrates, 20% proteins
|
Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 15% fat, 65% carbohydrate, 20% protein content.
|
|
Active Comparator: Standard healthy diet arm
Daily calorie intake will be composed of 30% fat, 50% carbohydrates and 20% proteins.
|
Participants will receive a dietary intervention, and will be proposed to adhere to a diet with a 30% fat, 50% carbohydrate, 20% protein content.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of recurrent acute pancreatitis and/or all-cause mortality
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
The recurrence of acute pancreatitis (given as a rate of event) AND/OR all-cause mortality.
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of pancreas specific mortality
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Mortality of a pancreatic cause
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Proportion of cardiosvascular cause mortality
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Mortality of a cardiovascular cause.
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Proportion of newly diagnosed chronic pancreatitis patients
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Newly diagnosed chronic pancreatitis.
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Changes in BMI
Time Frame: Data will be recorded az baseline, and during the 3-6-12-18-24 months followup visits
|
Changes in BMI compared to baseline both in total and percentage
|
Data will be recorded az baseline, and during the 3-6-12-18-24 months followup visits
|
|
Serum total cholesterol
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Serum total cholesterol absolute value
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Change in serum total cholesterol
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Serum total cholesterol compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Serum triglyceride
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Serum triglyceride absolute value
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Change in serum triglyceride
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Serum triglyceride compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Serum high density liporpotein(HDL)-cholesterol
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Serum high density liporpotein(HDL)-cholesterol absolute value
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Change in serum high density liporpotein(HDL)-cholesterol
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Serum high density liporpotein(HDL)-cholesterol compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Serum low density liporpotein(LDL)-cholesterol
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Serum low density liporpotein(LDL)-cholesterol absolute value
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Change in serum low density liporpotein(LDL)-cholesterol
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Serum low density liporpotein(LDL)-cholesterol compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Systolic blood pressure value
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Systolic blood pressure absolute value
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Change in systolic blood pressure
Time Frame: Data will be recorded az baseline, and during the 3-6-12-18-24 months followup visits
|
Systolic blood pressure compared to baseline
|
Data will be recorded az baseline, and during the 3-6-12-18-24 months followup visits
|
|
Diastolic blood pressure
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Diastolic blood pressure absolute value
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Change in siastolic blood pressure
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Diastolic blood pressure compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Adherence to dietary recommendations as determined by the result of the food frequency questionnaire
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Adherence to dietary recommendations as determined by the result of the food frequency questionnaire
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Adverse effects
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Adverse effects given as rate of events
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Serum albumin value
Time Frame: Data will be recorded during the 3-6-12-18-24 months followup visits
|
Serum albumin absolute value
|
Data will be recorded during the 3-6-12-18-24 months followup visits
|
|
Change in serum albumin value
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Serum albumin value compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Proportion of current smokers
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Current smoking at each visit
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Quality of life questionnaire on mobility, self-care, usual activities, pain/discomfort and anxiety/depression
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Quality of life assessed by the EQ-5D-5L questionnaire
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Muscle strength
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Muscle strength using a handgrip dynamometer
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Vitamin A value
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Vitamin A absolute value
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Change in vitamin A value
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Change in vitamin A value compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Vitamin D value
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Vitamin D absolute value
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Change in vitamin D value
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Change in vitamin D value compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Vitamin E value
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Vitamin E absolute value
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Change in vitamin E value
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Change in vitamin E value compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Vitamin K value
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Vitamin K absolute value
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Change in vitamin K value
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Change in vitamin K value compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Change in smoking
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Change in smoking compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Change in quality of life
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Change in quality of life assessed by the EQ-5D-5L questionnaire compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
|
Change in muscle strength
Time Frame: Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Change in muscle strength using a handgrip dynamometer compared to baseline
|
Data will be recorded at baseline, and during the 3-6-12-18-24 months followup visits
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Péter Hegyi, MD, PhD, DSc, Insitute for Translational Medicine, University of Pécs, Medical School, Pécs, Hungary
Publications and helpful links
General Publications
- Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013 Sep;108(9):1400-15; 1416. doi: 10.1038/ajg.2013.218. Epub 2013 Jul 30. Erratum In: Am J Gastroenterol. 2014 Feb;109(2):302.
- Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ, Bucher HC. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006 Feb 13;166(3):285-93. doi: 10.1001/archinte.166.3.285. Erratum In: Arch Intern Med. 2006 Apr 24;166(8):932.
- Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013 Jul-Aug;13(4 Suppl 2):e1-15. doi: 10.1016/j.pan.2013.07.063.
- Mansoor N, Vinknes KJ, Veierod MB, Retterstol K. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. Br J Nutr. 2016 Feb 14;115(3):466-79. doi: 10.1017/S0007114515004699.
- Spanier BW, Dijkgraaf MG, Bruno MJ. Epidemiology, aetiology and outcome of acute and chronic pancreatitis: An update. Best Pract Res Clin Gastroenterol. 2008;22(1):45-63. doi: 10.1016/j.bpg.2007.10.007.
- Sankaran SJ, Xiao AY, Wu LM, Windsor JA, Forsmark CE, Petrov MS. Frequency of progression from acute to chronic pancreatitis and risk factors: a meta-analysis. Gastroenterology. 2015 Nov;149(6):1490-1500.e1. doi: 10.1053/j.gastro.2015.07.066. Epub 2015 Aug 20.
- Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN; American Gastroenterological Association Institute Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on Initial Management of Acute Pancreatitis. Gastroenterology. 2018 Mar;154(4):1096-1101. doi: 10.1053/j.gastro.2018.01.032. Epub 2018 Feb 3. No abstract available.
- Prizment AE, Jensen EH, Hopper AM, Virnig BA, Anderson KE. Risk factors for pancreatitis in older women: the Iowa Women's Health Study. Ann Epidemiol. 2015 Jul;25(7):544-8. doi: 10.1016/j.annepidem.2014.12.010. Epub 2015 Jan 7.
- Setiawan VW, Pandol SJ, Porcel J, Wei PC, Wilkens LR, Le Marchand L, Pike MC, Monroe KR. Dietary Factors Reduce Risk of Acute Pancreatitis in a Large Multiethnic Cohort. Clin Gastroenterol Hepatol. 2017 Feb;15(2):257-265.e3. doi: 10.1016/j.cgh.2016.08.038. Epub 2016 Sep 5.
- Oskarsson V, Sadr-Azodi O, Discacciati A, Orsini N, Wolk A. Overall diet quality and risk of recurrence and progression of non-gallstone-related acute pancreatitis: a prospective cohort study. Eur J Nutr. 2018 Oct;57(7):2537-2545. doi: 10.1007/s00394-017-1526-8. Epub 2017 Aug 30.
- Cuevas A, Miquel JF, Reyes MS, Zanlungo S, Nervi F. Diet as a risk factor for cholesterol gallstone disease. J Am Coll Nutr. 2004 Jun;23(3):187-96. doi: 10.1080/07315724.2004.10719360.
- Thomas T, Mah L, Barreto SG. Systematic review of diet in the pathogenesis of acute pancreatitis: a tale of too much or too little? Saudi J Gastroenterol. 2012 Sep-Oct;18(5):310-5. doi: 10.4103/1319-3767.101124.
- Lindkvist B, Appelros S, Regner S, Manjer J. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. Pancreatology. 2012 Jul-Aug;12(4):317-24. doi: 10.1016/j.pan.2012.05.002. Epub 2012 May 10.
- Cappell MS. Acute pancreatitis: etiology, clinical presentation, diagnosis, and therapy. Med Clin North Am. 2008 Jul;92(4):889-923, ix-x. doi: 10.1016/j.mcna.2008.04.013.
- Biczo G, Vegh ET, Shalbueva N, Mareninova OA, Elperin J, Lotshaw E, Gretler S, Lugea A, Malla SR, Dawson D, Ruchala P, Whitelegge J, French SW, Wen L, Husain SZ, Gorelick FS, Hegyi P, Rakonczay Z Jr, Gukovsky I, Gukovskaya AS. Mitochondrial Dysfunction, Through Impaired Autophagy, Leads to Endoplasmic Reticulum Stress, Deregulated Lipid Metabolism, and Pancreatitis in Animal Models. Gastroenterology. 2018 Feb;154(3):689-703. doi: 10.1053/j.gastro.2017.10.012. Epub 2017 Oct 23.
- Zhang X, Cui Y, Fang L, Li F. Chronic high-fat diets induce oxide injuries and fibrogenesis of pancreatic cells in rats. Pancreas. 2008 Oct;37(3):e31-8. doi: 10.1097/MPA.0b013e3181744b50.
- Czako L, Szabolcs A, Vajda A, Csati S, Venglovecz V, Rakonczay Z Jr, Hegyi P, Tiszlavicz L, Csont T, Posa A, Berko A, Varga C, Varga Ilona S, Boros I, Lonovics J. Hyperlipidemia induced by a cholesterol-rich diet aggravates necrotizing pancreatitis in rats. Eur J Pharmacol. 2007 Oct 15;572(1):74-81. doi: 10.1016/j.ejphar.2007.05.064. Epub 2007 Jun 13.
- Nordback I, Pelli H, Lappalainen-Lehto R, Jarvinen S, Raty S, Sand J. The recurrence of acute alcohol-associated pancreatitis can be reduced: a randomized controlled trial. Gastroenterology. 2009 Mar;136(3):848-55. doi: 10.1053/j.gastro.2008.11.044. Epub 2008 Nov 27.
- Bueno NB, de Melo IS, de Oliveira SL, da Rocha Ataide T. Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. Br J Nutr. 2013 Oct;110(7):1178-87. doi: 10.1017/S0007114513000548. Epub 2013 May 7.
- Lu M, Wan Y, Yang B, Huggins CE, Li D. Effects of low-fat compared with high-fat diet on cardiometabolic indicators in people with overweight and obesity without overt metabolic disturbance: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr. 2018 Jan;119(1):96-108. doi: 10.1017/S0007114517002902. Epub 2017 Dec 7.
- Marta K, Szabo AN, Pecsi D, Varju P, Bajor J, Godi S, Sarlos P, Miko A, Szemes K, Papp M, Tornai T, Vincze A, Marton Z, Vincze PA, Lanko E, Szentesi A, Molnar T, Hagendorn R, Faluhelyi N, Battyani I, Kelemen D, Papp R, Miseta A, Verzar Z, Lerch MM, Neoptolemos JP, Sahin-Toth M, Petersen OH, Hegyi P; Hungarian Pancreatic Study Group. High versus low energy administration in the early phase of acute pancreatitis (GOULASH trial): protocol of a multicentre randomised double-blind clinical trial. BMJ Open. 2017 Sep 14;7(9):e015874. doi: 10.1136/bmjopen-2017-015874.
- Parniczky A, Mosztbacher D, Zsoldos F, Toth A, Lasztity N, Hegyi P; Hungarian Pancreatic Study Group and the International Association of Pancreatology. Analysis of Pediatric Pancreatitis (APPLE Trial): Pre-Study Protocol of a Multinational Prospective Clinical Trial. Digestion. 2016;93(2):105-10. doi: 10.1159/000441353. Epub 2015 Nov 26.
- Miko A, Eross B, Sarlos P, Hegyi P Jr, Marta K, Pecsi D, Vincze A, Bodis B, Nemes O, Faluhelyi N, Farkas O, Papp R, Kelemen D, Szentesi A, Hegyi E, Papp M, Czako L, Izbeki F, Gajdan L, Novak J, Sahin-Toth M, Lerch MM, Neoptolemos J, Petersen OH, Hegyi P. Observational longitudinal multicentre investigation of acute pancreatitis (GOULASH PLUS): follow-up of the GOULASH study, protocol. BMJ Open. 2019 Sep 3;9(8):e025500. doi: 10.1136/bmjopen-2018-025500.
- Zadori N, Gede N, Antal J, Szentesi A, Alizadeh H, Vincze A, Izbeki F, Papp M, Czako L, Varga M, de-Madaria E, Petersen OH, Singh VP, Mayerle J, Faluhelyi N, Miseta A, Reiber I, Hegyi P. EarLy Elimination of Fatty Acids iN hypertriglyceridemia-induced acuTe pancreatitis (ELEFANT trial): Protocol of an open-label, multicenter, adaptive randomized clinical trial. Pancreatology. 2020 Apr;20(3):369-376. doi: 10.1016/j.pan.2019.12.018. Epub 2019 Dec 30.
- Parniczky A, Abu-El-Haija M, Husain S, Lowe M, Oracz G, Sahin-Toth M, Szabo FK, Uc A, Wilschanski M, Witt H, Czako L, Grammatikopoulos T, Rasmussen IC, Sutton R, Hegyi P. EPC/HPSG evidence-based guidelines for the management of pediatric pancreatitis. Pancreatology. 2018 Mar;18(2):146-160. doi: 10.1016/j.pan.2018.01.001. Epub 2018 Jan 4.
- Hritz I, Czako L, Dubravcsik Z, Farkas G, Kelemen D, Lasztity N, Morvay Z, Olah A, Pap A, Parniczky A, Sahin-Toth M, Szentkereszti Z, Szmola R, Szucs A, Takacs T, Tiszlavicz L, Hegyi P; Magyar Hasnyalmirigy Munkacsoport, Hungarian Pancreatic Study Group. [Acute pancreatitis. Evidence-based practice guidelines, prepared by the Hungarian Pancreatic Study Group]. Orv Hetil. 2015 Feb 15;156(7):244-61. doi: 10.1556/OH.2015.30059. Hungarian.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 40304-11/2020/EÜIG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.